Reporting owner · CIK 0001742485

Kumar Neil

SEC Form 4 history for the last 180 days across 1 company, 23 transactions and 4 filings.

CEOChief Executive OfficerBridgeBio Pharma, Inc.
Open-market transaction mix0% buys0 buys · 14 sales

Period: Last 180 days

Trade dates in this period: May 21, 2026 – Sep 17, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings4Form 4 records
Buying$00 purchases
Selling$6.23M14 sales
Net value−$6.23MBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
Kumar Neil transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
BBIOBridgeBio Pharma, Inc.
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$89.0kView disclosure →
BBIOBridgeBio Pharma, Inc.
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$602kView disclosure →
BBIOBridgeBio Pharma, Inc.
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$8.57kView disclosure →
BBIOBridgeBio Pharma, Inc.
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$152kView disclosure →
BBIOBridgeBio Pharma, Inc.
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$679kView disclosure →
BBIOBridgeBio Pharma, Inc.
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$100kView disclosure →
BBIOBridgeBio Pharma, Inc.
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$1.21MView disclosure →
BBIOBridgeBio Pharma, Inc.
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$1.42MView disclosure →
BBIOBridgeBio Pharma, Inc.
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$154kView disclosure →
BBIOBridgeBio Pharma, Inc.
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
$0View disclosure →
BBIOBridgeBio Pharma, Inc.
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
$0View disclosure →
BBIOBridgeBio Pharma, Inc.
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
$0View disclosure →
BBIOBridgeBio Pharma, Inc.
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Derivative securitySEC filing ↗
$0View disclosure →
BBIOBridgeBio Pharma, Inc.
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Tax withholding
Form 4 code F. Payment of an exercise price or tax liability by delivering or withholding securities in a Rule 16b-3 transaction.
SEC filing ↗
−$2.89MView disclosure →
BBIOBridgeBio Pharma, Inc.
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
SEC filing ↗
—View disclosure →
BBIOBridgeBio Pharma, Inc.
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
SEC filing ↗
—View disclosure →
BBIOBridgeBio Pharma, Inc.
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
SEC filing ↗
—View disclosure →
BBIOBridgeBio Pharma, Inc.
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
SEC filing ↗
—View disclosure →
BBIOBridgeBio Pharma, Inc.
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$56.7kView disclosure →
BBIOBridgeBio Pharma, Inc.
CEO
CEO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$793kView disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a sale at BridgeBio Pharma, Inc. on Sep 17, 2026 valued at $88,979.52.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Monthly open-market activity

Last 3 reported months · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
May 202605$0$1,812,521.76−$1,812,521.76
Aug 202607$0$3,727,250.87−$3,727,250.87
Sep 202602$0$690,847.13−$690,847.13

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$445k
Median P/S size$253k
Direct18
Indirect5
Sep 17, 2026sale

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
No open-market purchases in the last 180 days

A 90-day purchase return requires an open-market buy. None is recorded in the last 180 days. Purchases filed earlier are outside the visible history and are not included.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

5 observations · Aug 19, 2026 – Sep 17, 2026. Window ends at the latest available report, not today.

Selected observation · Sep 17, 2026495,686 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Aug 19, 2026507,586Aug 20, 2026View transaction
Aug 19, 2026505,786Aug 20, 2026View transaction
Aug 19, 2026505,686Aug 20, 2026View transaction
Sep 17, 2026496,965Sep 21, 2026View transaction
Sep 17, 2026495,686Sep 21, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Kumar Neil Insider Activity FAQ

SEC Form 4 context

Who is Kumar Neil?

Kumar Neil is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001742485.

Which companies has Kumar Neil reported transactions for?

BridgeBio Pharma, Inc., Maze Therapeutics, Inc.

When was Kumar Neil's latest insider buy?

No open-market insider purchase is recorded in the last 180 days. Earlier filings are outside the visible history.

When was Kumar Neil's latest insider sale?

The insider reported a sale at BridgeBio Pharma, Inc. on Sep 17, 2026 valued at $88,979.52.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.